Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Why did ABC pull Jimmy Kimmel's show? How will Fed rate cut impact markets? What caused Spirit Airlines job cuts? Why did Ben & Jerry's co-founder resign? How is China’s AI chip ban affecting Nvidia? What’s behind Meta’s new smart glasses launch? Why is Cracker Barrel losing restaurant traffic?

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

benzinga.com/markets/large-cap/25/09/47725129/johnson-johnson-protagonist-study-shows-superior-skin-clearance-in-psoriasis-trials

Johnson & Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.
Icotrokinra met both co-primary…

This story appeared on benzinga.com, 2025-09-17 19:15:33.